OTC Medical Device Bottleneck Will Have 'Serious Implications' For German Industry, Says BAH’s Dr Cranz
In an exclusive interview with HBW Insight, the German Medicines Manufacturers´ Association’s (BAH’s) new director general Dr Hubertus Cranz warns of a potentially costly bottleneck forming as German manufacturers scramble to re-certify their self-care medical devices before the May 2020 European Union's new Medical Device Regulations deadline. Dr Cranz also explains how BAH is supporting the country's community pharmacists to help German consumers to self-care safely and responsibly.
You may also be interested in...
Bayer's Iberogast is in the spotlight in Germany. According to media reports, a German court is investigating a 2018 Iberogast-related death as a possible case of manslaughter and bodily harm caused by negligence. Bayer is standing behind its product, stating that the death was “most probably” due to an “idiosyncratic reaction.”
German Industry Tries To Nip Homeopathy Debate In The Bud As France Decides In Favour Of De-Reimbursement
As France decides to de-reimburse homeopathic medicines, discussions about whether this should be applied to Germany are being re-opened by politicians and high-profile representatives from the country's statutory health insurance system. Industry has responded by saying "no" to de-reimbursement, as the German system allows consumers to choose between insurers based on their views of homeopathy.
German Switch Committee Meets: Sumatriptan Goes Again, Antihistamine Reverse-Switch Rejected, For Now
Germany’s Expert Committee for Prescription recommends prescription-to-OTC reclassifications of sumatriptan for migraines and liquid ibuprofen, but rejects an OTC switch for ketoprofen and the reverse-switch of sedative antihistamines for over 65s.